Yingjiang Ye

Abstract Elevated intratumoral immune inflammation prior to treatment is typically associated with better outcomes in hot tumors treated with immune checkpoint inhibitors (ICIs). However, we observed a paradox in pMMR/MSS locally advanced rectal cancer (LARC) patients, where a subset with elevated baseline immune inflammation exhibited worse outcomes after combined radiotherapy and ICI treatment compared with patients with minimal immune inflammation.

Abstract Microsatellite-stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) is characterized by a cold tumor microenvironment, with limited CD8⁺ T cell infiltration and poor responsiveness to immune checkpoint inhibitors (ICIs). Here, using an in vivo CRISPR/Cas9 screen in a CMT93 cell-derived murine tumor model, we identify Arid3b as a key negative regulator of CD8⁺ T cell infiltration and antitumor activity.

OVERVIEW In 2020, Li and Shen provided a detailed overview of the status of gastrointestinal stromal tumor (GIST) research in China.1 In recent years, significant attention has been paid to GIST research and treatment in China. This editorial briefly presents an update on the diagnosis and treatment of GISTs in China, as well as the differences between China and Western countries.